Compare IDEXX Laboratories, Inc. (IDXX) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Tesla, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $556.84 (market cap $44.48B), while Tesla, Inc. trades at $382.36 (market cap $1.39T). The key difference: Tesla, Inc. is far larger — about 31.3× IDEXX Laboratories, Inc.'s market cap, and Tesla, Inc. is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | TSLA | |
|---|---|---|
Market Cap | $44.48B | $1.39T |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $489.88 |
52-Week Low | $520.87 | $302.63 |
Enterprise Value | $45.38B | $1.36T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Tesla (TSLA) trades at $382.42, up 0.41% on the day, but faces a bearish technical signal with the price below key moving averages. The stock is valued at a high P/E of 339.06, reflecting significant growth expectations despite a recent decline in net income margin to 3.95%. Recent news highlights regulatory approval for its driver-assistance software in Europe and a potential cheaper EV model, offering growth catalysts amid competitive pressures.
The outlook for Tesla hinges on successful execution in autonomous driving and energy segments to justify its premium valuation. Key risks include intense EV competition and macroeconomic sensitivity, while analyst sentiment is mixed with a consensus price target of $409.26, suggesting modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
